[Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in patients with chronic hepatitis B

Yu-Lin Zhou1, Xue-Cai Wang, Yin-Tao Wu

  • 1Dept. of Infection, Yixing People's Hospital, Yixing 214200, China. zhouyl972@163.com

Insights

Adefovir dipivoxil treatment increased HBV specific cellular immunity in chronic hepatitis B patients. HBeAg seroconversion was linked to higher HBV specific CTL levels and potentially influenced by HBV genotypes.

Area of Science:

  • Hepatology
  • Immunology
  • Virology

Background:

  • Chronic hepatitis B (CHB) is a persistent viral infection.
  • HBeAg seroconversion is a key indicator of treatment response in CHB.
  • HBV genotypes and cellular immunity play roles in CHB progression and treatment outcomes.

Purpose of the Study:

  • To investigate the relationship between HBeAg seroconversion, HBV genotypes, and HBV specific CTL response.
  • To evaluate the efficacy of Adefovir dipivoxil in modulating these factors in CHB patients.

Main Methods:

  • Seventy CHB patients with detectable HBV DNA were enrolled.
  • Patients received Adefovir dipivoxil (10 mg daily) for 12 months.
  • HBV DNA levels, HBeAg status, HBV specific CTL, and HBV genotypes (B and C) were monitored.

Main Results:

  • Adefovir dipivoxil treatment significantly increased HBV specific CTL and decreased HBV DNA levels.
  • HBeAg seroconversion occurred in 17.78% of patients, with higher CTL levels observed in those who achieved seroconversion.
  • HBeAg seroconversion was more frequent in patients with HBV genotype B compared to genotype C.

Conclusions:

  • Adefovir dipivoxil enhances HBV specific cellular immunity in CHB patients.
  • Increased HBV specific CTL levels are associated with HBeAg seroconversion.
  • HBV genotypes may influence the occurrence of HBeAg seroconversion during Adefovir dipivoxil treatment.
Abstract